Manufacturing Plants Laboratorios Richmond Argentina
From Argentina to the world
Laboratorios Richmond has two plants where pharmaceutical forms of pharmacological and chemical products are manufactured. A third biotechnology plant is under construction. The three units are located in an industrial park located in Pilar city, Buenos Aires Province. This location is central to the pharmaceutical development, the manufacturing process and the logistics of our Company.
In addition to manufacturing pharmaceutical products, both plants are fitted with areas devoted to the development of new products, manufacturing of samples for clinical trials and technology transfer. We also perform quality control tasks of all our processes and coordinate the Logistics and Distribution Department.
The UPEF (Unidad Productiva Líneas Especiales y Farma - Productive Unit of Special Lines and Pharma) plant is 5,600 square meters devoted to manufacturing solid oral dosage forms for the treatment of HIV, and also for cardiometabolic and neurodegenerative diseases. It is equipped with the most advanced technologies and is in full compliance with international standards, cGMP and the PIC Scheme.
To consolidate the international presence the plant has been qualified according to the quality risk management criteria and it has been certified for ISO 9001 and ISO 14001 of good environmental practices, both validated by IQNET (The International Certification Network).
The UPAP (Unidad Productiva de Alta Potencia – High Potency Production Unit) plant is 1,800 square meters and is the center of excellence of the Company where we manufacture special solid oral forms including complex and potent active ingredients indicated for advanced therapies, such as oncologic and multiple sclerosis treatments. Due to the high biological activity of these molecules, the plant is equipped with unrivalled technology in the Region, which guarantees a high level of protection with 100% primary containment during material loading, unloading and manipulation using closed valves and systems.
There is no contact of the substance with the operator or with the environment. This process also allows for an adequate cleaning and lowers the risk of contamination. All that boosts the performance of our processes, taking into account that we use molecules of an extremely high cost.
The VIDA plant is a unit currently under construction devoted to manufacturing the end-to-end production cycle, for both vaccines and for complex biotechnological products.
More than 10,000 square meters will be devoted to raw material and finished product manufacturing. A pilot plant and laboratory premises will also be built. The plant is being equipped with “single use” technology and will have fully independent areas along two lines to provide for maximum flexibility.